Procedures
bloating, diarrhea, abdominal pain, TEAEs, constipation, skin rash, nausea,, headache
ADVERSE EVENTS, SECONDARY, CONCOMITANT DISEASE
To begin with, the detailed demographics and characteristics of the subjects included in this study were recorded, including sex, age, nationality, height, weight, education status, dwelling area, history of smoking and alcohol, concomitant diseases, and medication history. In addition, physical examinations and assessments of vital signs were performed.During (or after) treatment-emergent adverse events (TEAEs) and concomitant medication were recorded throughout the study, including bloating, nausea, vomiting, abdominal pain, diarrhea, constipation, skin rash, headache, and hunger sensation. All TEAEs were divided into mild, moderate, and severe. TEAEs leading to the discontinuation of the study drug were also recorded. The confirmation of The primary outcome of the study was the eradication rate of the different regimens according to ITT and PP analyses. The ITT analysis included all randomized patients. Patients who were lost to follow-up or did not achieve >80% of drug compliance or did not undergo UBT were excluded from the PP analysis. The secondary outcomes were the frequency and severity of TEAEs and adherence.